Search SYK
Stryker Corporation
NYSE · CIK 310764
Last close275.43
Daily change+2.47 (0.90%)
10 Years gain+159.14%
Dividends TTM3.52 (+4.76%)
Dividend yield1.29%
Fundamental Analysis
SYK · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
50.3Momentum
66.2Acceleration
66.2Confidence
78.0Annual Revenue19
Quarterly Revenue88
Annual CFO19
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.9 / 25
Quality19.7 / 25
Capital Efficiency0.0 / 20
Balance Sheet7.7 / 15
Shareholder Economics8.4 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.8402 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 0.1035%.
Key Metrics
Revenue Growth TTM8.48%OK
Revenue CAGR 3Y10.83%OK
Gross Margin64.98%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-0.1%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $25.12B | $16.07B | $4.89B | $5.04B | $4.28B | 63.96% | 19.47% | 17.05% | 10.87% | 386.5M |
| 2025 FY Dec 31, 2024 | $22.60B | $14.44B | $3.69B | $4.24B | $3.49B | 63.91% | 16.33% | 15.43% | 10.71% | 385.6M |
| 2025 FY Dec 31, 2023 | $20.50B | $13.06B | $3.89B | $3.71B | $3.14B | 63.7% | 18.97% | 15.3% | 11.91% | 383.7M |
| 2024 FY Dec 31, 2022 | $18.45B | $11.58B | $2.84B | $2.62B | $2.04B | 62.76% | 15.4% | 11.04% | 9.59% | 382.2M |
| 2023 FY Dec 31, 2021 | $17.11B | $10.97B | $2.58B | $3.26B | $2.74B | 64.11% | 15.1% | 16% | 9.34% | 382.3M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $25.84B | sum latest 4 fiscal quarters Revenue | OK | 0000310764-26-000010, 0000310764-26-000031 |
| Revenue Growth TTM | 8.48% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000310764-26-000010, 0000310764-26-000031 |
| Revenue CAGR 3Y | 10.83% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000310764-26-000010 |
| Revenue CAGR 5Y | 11.84% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000310764-26-000010 |
| Gross Profit CAGR 3Y | 11.54% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000310764-26-000010 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | +3.23 pp | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | OK | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 64.98% | Gross Profit / Revenue | OK | 0000310764-26-000010, 0000310764-26-000031 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000310764-26-000050 |
| Current Ratio | 2.16x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.23x | (Cash + Short-term Investments) / Total Debt | OK | 0000310764-26-000050 |
| Revenue per Diluted Share | $66.94 | Revenue / Diluted Shares | OK | 0000310764-26-000010, 0000310764-26-000031 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | 39.56% | Cash dividends paid / Net income | OK | 0000310764-26-000010 |